歐洲新聞 English-Oral Antianginal Drug口服抗心絞痛藥物市場數(shù)據(jù) 英語 John

QYResearch|market@|

EuropeanOralAntianginalDrugMarketSettoReach€2.68Billionby2031ata3.8%CAGR

Geneva,Switzerland—January23,2025

EuropeanOralAntianginalDrugsMarket

AccordingtoQYResearch,Novartishasrecentlydemonstratedstrongmomentuminitsstrategicfocusoninnovativemedicines,emphasizingfivecoretherapeuticareasandkeytechnologyplatforms.InNovember2024,thecompanyupgradeditsmid-termsalesguidance,projectingacompoundannualgrowthrate(CAGR)of5%from2024to2029.Thisoptimisticoutlookisdrivenbyrobustin-marketgrowthdriversandanexpandingpipelineofproductlaunches,showcasingNovartis’commitmenttogrowthacrossitsmarkets.TheseeffortsalignwiththeEuropeanOralAntianginalDrugsmarket,asthecompanycontinuestocapitalizeonitsinnovativetherapeuticdevelopmentsandleadershipincardiovasculartreatments.

Inthesamevein,AstraZenecahasachievedasignificantmilestonewithitscardiovascularportfolio.AsreportedbyQYResearch,thecompany’sAndexxa,atreatmentdesignedtoreverseanticoagulationeffectscausedbyoralFXainhibitors,metitsefficacyendpointaheadofscheduleintheANNEXA-IphaseIVstudy.Thisbreakthrough,announcedinmid-2024,reinforcesAstraZeneca’sdedicationtoadvancingcardiovasculartherapiesanditsimpactfulroleintheEuropeanpharmaceuticallandscape.Withanincreasingemphasisonresearchanddevelopmentinantianginalandrelatedtherapies,AstraZenecacontinuestostrengthenitscompetitivepositionwithintheEuropeanOralAntianginalDrugsmarket.

TheEuropeanmarketforOralAntianginalDrugswasestimatedtobeworth€2067.1millionin2024andisforecasttoareadjustedsizeof€2683.8millionby2031withaCAGRof3.8%duringtheforecastperiod2025-2031.

EuropeanOralAntianginalDrugsTop20PlayersRankingandMarketShare(Rankingisbasedontherevenueof2024,continuallyupdated)

·Novartis(Switzerland)

·AstraZeneca(UnitedKingdom)

·Pfizer(UnitedStates)

·Sanofi(France)

·BayerAG(Germany)

·Merck&Co.(UnitedStates)

·GSK(GlaxoSmithKline)(UnitedKingdom)

·BoehringerIngelheim(Germany)

·EliLillyandCompany(UnitedStates)

·AbbVie(UnitedStates)

·Bristol-MyersSquibb(UnitedStates)

·TevaPharmaceuticalIndustries(Israel)

·TakedaPharmaceuticalCompany(Japan)

·DaiichiSankyo(Japan)

·Amgen(UnitedStates)

·Roche(Switzerland)

·Mylan(UnitedStates)

·LupinLimited(India)

·SunPharmaceuticalIndustries(India)

·Dr.Reddy'sLaboratories(India)

3.OralAntianginalDrugs,EuropeanMarketSize,SplitbyRegion

OralAntianginalDrugs,EuropeanMarketSize,SplitbyProductSegment

5.OralAntianginalDrugs,EuropeanMarketSize,SplitbyApplicationSegment

BasedonorincludesresearchfromQYResearch:GlobalandEuropeanOralAntianginalDrugsMarketReport2025-2031

RelatedMarketReportsFromQYResearch

QYResearchReleasesComprehensiveMarketReportsontheOralAntianginalDrugsMarket,asshowninthelinksbelow.Thesereportsprovideanin-depthanalysisofthecurrentmarketlandscape,keytrends,andfuturegrowthopportunities.

OralAntianginalDrugs-GlobalMarketShareandRanking,OverallSalesandDemandForecast2025-2031

reports/3552052/oral-antianginal-drugs

GlobalOralAntianginalDrugsMarketResearchReport2025

reports/35520